SEC Comment Letter 0000000000-23-003924 to GALECTIN THERAPEUTICS INC (GALT)
GALECTIN THERAPEUTICS INC
Date: April 19, 2023 · CIK: 0001133416 · Accession: 0000000000-23-003924
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-271278
Letter
United States securities and exchange commission logo April 19, 2023 Joel Lewis Chief Executive Officer and President GALECTIN THERAPEUTICS INC 4960 Peachtree Industrial Blvd., Suite 240 Norcross, GA 30071 Re:GALECTIN THERAPEUTICS INC Registration Statement on Form S-3 Filed April 14, 2023 File No. 333-271278 Dear Joel Lewis: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Arzhang Navai at 202-551-4676 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Brian Lee
Show Raw Text
United States securities and exchange commission logo
April 19, 2023
Joel Lewis
Chief Executive Officer and President
GALECTIN THERAPEUTICS INC
4960 Peachtree Industrial Blvd., Suite 240
Norcross, GA 30071
Re:GALECTIN THERAPEUTICS INC
Registration Statement on Form S-3
Filed April 14, 2023
File No. 333-271278
Dear Joel Lewis:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Arzhang Navai at 202-551-4676 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Brian Lee